Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) and Xometry (NASDAQ:XMTR – Get Free Report) are both industrials companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
Institutional & Insider Ownership
23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 97.3% of Xometry shares are held by institutional investors. 23.7% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 9.1% of Xometry shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Cyclacel Pharmaceuticals and Xometry’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclacel Pharmaceuticals | N/A | -51.21% | -44.00% |
| Xometry | -3.82% | -2.88% | -1.29% |
Risk and Volatility
Analyst Recommendations
This is a summary of current recommendations for Cyclacel Pharmaceuticals and Xometry, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclacel Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Xometry | 1 | 4 | 6 | 0 | 2.45 |
Xometry has a consensus price target of $101.88, indicating a potential upside of 7.84%. Given Xometry’s stronger consensus rating and higher possible upside, analysts clearly believe Xometry is more favorable than Cyclacel Pharmaceuticals.
Valuation & Earnings
This table compares Cyclacel Pharmaceuticals and Xometry”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclacel Pharmaceuticals | $750,000.00 | 6.81 | -$3.00 million | ($4.54) | -0.20 |
| Xometry | $686.63 million | 7.13 | -$61.74 million | ($0.60) | -157.45 |
Cyclacel Pharmaceuticals has higher earnings, but lower revenue than Xometry. Xometry is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Xometry beats Cyclacel Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
About Xometry
Xometry, Inc. operates an online marketplace that enables buyers to source custom-manufactured parts and assemblies in the United States and internationally. It provides computer numerical control manufacturing, sheet metal forming, and sheet cutting; 3D printing, including fused deposition modeling, direct metal laser sintering, PolyJet, stereolithography, selective laser sintering, binder jetting, carbon digital light synthesis, multi jet fusion, and lubricant sublayer photo-curing; and die casting, stamping, injection molding, urethane casting, tube cutting, and tube bending, as well as finishing services, rapid prototyping, and high-volume production services. It serves aerospace, healthcare, robotics, industrial, defense, energy, automotive, government, education, and consumer goods industries. The company was formerly known as NextLine Manufacturing Corp. and changed its name to Xometry, Inc. in June 2015. Xometry, Inc. was incorporated in 2013 and is headquartered in North Bethesda, Maryland.
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
